Treatment of the seronegative spondyloarthropathies with sulfasalazine.

S. H. Zwillich, S. S. Comer, E. Lee, W. A. Erdman, P. E. Lipsky

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Three patients with reactive arthritis and 2 with ankylosing spondylitis resistant to therapy with nonsteroidal antiinflammatory drugs were treated with enteric coated sulfasalazine in an open trial. Significant toxicity was not observed; 1 patient discontinued sulfasalazine because of gastrointestinal symptoms. As a group, statistically significant improvement was observed in 50 foot walk time, morning stiffness, and hemoglobin concentration. One patient went into complete clinical remission, 2 improved, 1 showed no change, and 1 worsened. Asymptomatic colonic inflammation was found in each of 4 patients examined before beginning therapy. Changes in bowel pathology did not parallel changes in joint symptoms. Sulfasalazine may be a safe and useful therapeutic modality in patients with chronic reactive arthritis or ankylosing spondylitis.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalThe Journal of rheumatology. Supplement
Volume16
StatePublished - Sep 1988

Fingerprint

Spondylarthropathies
Sulfasalazine
Reactive Arthritis
Ankylosing Spondylitis
Therapeutics
Hemoglobins
Anti-Inflammatory Agents
Joints
Pathology
Inflammation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology
  • Rheumatology

Cite this

Zwillich, S. H., Comer, S. S., Lee, E., Erdman, W. A., & Lipsky, P. E. (1988). Treatment of the seronegative spondyloarthropathies with sulfasalazine. The Journal of rheumatology. Supplement, 16, 33-39.

Treatment of the seronegative spondyloarthropathies with sulfasalazine. / Zwillich, S. H.; Comer, S. S.; Lee, E.; Erdman, W. A.; Lipsky, P. E.

In: The Journal of rheumatology. Supplement, Vol. 16, 09.1988, p. 33-39.

Research output: Contribution to journalArticle

Zwillich, SH, Comer, SS, Lee, E, Erdman, WA & Lipsky, PE 1988, 'Treatment of the seronegative spondyloarthropathies with sulfasalazine.', The Journal of rheumatology. Supplement, vol. 16, pp. 33-39.
Zwillich, S. H. ; Comer, S. S. ; Lee, E. ; Erdman, W. A. ; Lipsky, P. E. / Treatment of the seronegative spondyloarthropathies with sulfasalazine. In: The Journal of rheumatology. Supplement. 1988 ; Vol. 16. pp. 33-39.
@article{c44e09c9ae4348af9181b3bd6db22410,
title = "Treatment of the seronegative spondyloarthropathies with sulfasalazine.",
abstract = "Three patients with reactive arthritis and 2 with ankylosing spondylitis resistant to therapy with nonsteroidal antiinflammatory drugs were treated with enteric coated sulfasalazine in an open trial. Significant toxicity was not observed; 1 patient discontinued sulfasalazine because of gastrointestinal symptoms. As a group, statistically significant improvement was observed in 50 foot walk time, morning stiffness, and hemoglobin concentration. One patient went into complete clinical remission, 2 improved, 1 showed no change, and 1 worsened. Asymptomatic colonic inflammation was found in each of 4 patients examined before beginning therapy. Changes in bowel pathology did not parallel changes in joint symptoms. Sulfasalazine may be a safe and useful therapeutic modality in patients with chronic reactive arthritis or ankylosing spondylitis.",
author = "Zwillich, {S. H.} and Comer, {S. S.} and E. Lee and Erdman, {W. A.} and Lipsky, {P. E.}",
year = "1988",
month = "9",
language = "English (US)",
volume = "16",
pages = "33--39",
journal = "The Journal of rheumatology. Supplement",
issn = "0380-0903",
publisher = "Journal of Rheumatology",

}

TY - JOUR

T1 - Treatment of the seronegative spondyloarthropathies with sulfasalazine.

AU - Zwillich, S. H.

AU - Comer, S. S.

AU - Lee, E.

AU - Erdman, W. A.

AU - Lipsky, P. E.

PY - 1988/9

Y1 - 1988/9

N2 - Three patients with reactive arthritis and 2 with ankylosing spondylitis resistant to therapy with nonsteroidal antiinflammatory drugs were treated with enteric coated sulfasalazine in an open trial. Significant toxicity was not observed; 1 patient discontinued sulfasalazine because of gastrointestinal symptoms. As a group, statistically significant improvement was observed in 50 foot walk time, morning stiffness, and hemoglobin concentration. One patient went into complete clinical remission, 2 improved, 1 showed no change, and 1 worsened. Asymptomatic colonic inflammation was found in each of 4 patients examined before beginning therapy. Changes in bowel pathology did not parallel changes in joint symptoms. Sulfasalazine may be a safe and useful therapeutic modality in patients with chronic reactive arthritis or ankylosing spondylitis.

AB - Three patients with reactive arthritis and 2 with ankylosing spondylitis resistant to therapy with nonsteroidal antiinflammatory drugs were treated with enteric coated sulfasalazine in an open trial. Significant toxicity was not observed; 1 patient discontinued sulfasalazine because of gastrointestinal symptoms. As a group, statistically significant improvement was observed in 50 foot walk time, morning stiffness, and hemoglobin concentration. One patient went into complete clinical remission, 2 improved, 1 showed no change, and 1 worsened. Asymptomatic colonic inflammation was found in each of 4 patients examined before beginning therapy. Changes in bowel pathology did not parallel changes in joint symptoms. Sulfasalazine may be a safe and useful therapeutic modality in patients with chronic reactive arthritis or ankylosing spondylitis.

UR - http://www.scopus.com/inward/record.url?scp=0023687239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023687239&partnerID=8YFLogxK

M3 - Article

C2 - 2903925

AN - SCOPUS:0023687239

VL - 16

SP - 33

EP - 39

JO - The Journal of rheumatology. Supplement

JF - The Journal of rheumatology. Supplement

SN - 0380-0903

ER -